MedTrace Logo

Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders

NCT00830115 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1045

Last updated 2012-05-08

Study results available
· View outcomes & findings →

Summary

The aim of the study was to evaluate the effect of pantoprazole on sleep disorders in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease). The prevalence and intensity of the sleep disorders were evaluated by a standardized questionnaire. The study was expected to provide further data on safety and tolerability of pantoprazole.

Conditions

  • Sleep Disorders
  • Non-Erosive Reflux Disease
  • Gastroesophageal Reflux Disease

Interventions

DRUG

Pantoprazole

Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).

Sponsors & Collaborators

  • Nycomed

    lead INDUSTRY

Principal Investigators

  • Thomas Bethke, MD, MBA · Nycomed Deutschland GmbH, 78467 Konstanz, Germany

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-05-31
Completion
2009-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00830115 on ClinicalTrials.gov